Innovating Bacterial Vaccines at Scale
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make protein antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
With this competitive advantage, VAX-24, Vaxcyte’s lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate being developed for the prevention of invasive pneumococcal disease and pneumonia, has the potential to be a best-in-class PCV in an already $7 billion global market that is poised to undergo significant growth. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Statement of changes in beneficial ownership of securities
Quarterly report which provides a continuing view of a company's financial position
|EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT|
Report of unscheduled material events or corporate event
|EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT|